{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=histamine+dihydrochloride&page=3",
    "query": {
      "intervention": "histamine dihydrochloride",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 101,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=histamine+dihydrochloride&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=histamine+dihydrochloride&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T03:07:46.733Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02342041",
      "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cognitive Disorders"
      ],
      "interventions": [
        {
          "name": "SUVN-G3031",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suven Life Sciences Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2014-09",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-10-14",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02342041"
    },
    {
      "nct_id": "NCT06241183",
      "title": "Famotidine and Antacids for Treatment of Dyspepsia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dyspepsia",
        "GERD",
        "Acid Reflux"
      ],
      "interventions": [
        {
          "name": "Intravenous Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Oral Maalox/ Mylanta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-11-09",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06241183"
    },
    {
      "nct_id": "NCT04840615",
      "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "LMB-100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "FDG-PET",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT CAP",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-06-11",
      "completion_date": "2022-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04840615"
    },
    {
      "nct_id": "NCT00949754",
      "title": "Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "honeybee venom (Apitoxin (Korea) Apitox (USA))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apimeds, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-10",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-05-05",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 4,
      "location_summary": "Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949754"
    },
    {
      "nct_id": "NCT01712009",
      "title": "NOLAN: Naproxen or Loratadine and Neulasta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Pain in Stage I - III Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Loratadine",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2012-11-01",
      "completion_date": "2015-03-18",
      "has_results": true,
      "last_update_posted_date": "2018-01-30",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 83,
      "location_summary": "Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712009"
    },
    {
      "nct_id": "NCT01059786",
      "title": "Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Pentostatin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Epinephrine",
          "type": "DRUG"
        },
        {
          "name": "Antihistamines",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "Bronchodilators",
          "type": "DRUG"
        },
        {
          "name": "Intravenous (IV) Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2010-07-01",
      "completion_date": "2031-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059786"
    },
    {
      "nct_id": "NCT01689363",
      "title": "Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Skin Reaction"
      ],
      "interventions": [
        {
          "name": "Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Histamine",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphastar Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 253,
      "start_date": "2012-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 5,
      "location_summary": "Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Lake Oswego",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Renton",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01689363"
    },
    {
      "nct_id": "NCT00809692",
      "title": "In Vivo Assessment of Histamine Pharmacodynamics",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Histamine Biotransformation"
      ],
      "interventions": [
        {
          "name": "validated techniques for histamine response",
          "type": "PROCEDURE"
        },
        {
          "name": "new technique for histamine response",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Mercy Hospital Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "7 Years to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-09",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2021-01-07",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00809692"
    },
    {
      "nct_id": "NCT01204866",
      "title": "Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Reactions"
      ],
      "interventions": [
        {
          "name": "Valortim and selected Components",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valortim and Selected Components",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "PharmAthene, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 5,
      "start_date": "2010-07",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2010-09-24",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204866"
    },
    {
      "nct_id": "NCT02966665",
      "title": ": Vascular Function in Health and Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Pulmonary Artery Hypertension",
        "Heart Failure",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Maximum Exercise Tests",
          "type": "OTHER"
        },
        {
          "name": "BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate",
          "type": "DRUG"
        },
        {
          "name": "BQ-123",
          "type": "DRUG"
        },
        {
          "name": "Fexofenadine, Ranitidine",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin-II, Valsartan",
          "type": "OTHER"
        },
        {
          "name": "Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine",
          "type": "DRUG"
        },
        {
          "name": "BQ-123, MitoQ, BH4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "D. Walter Wray",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2008-09",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-07T03:07:46.733Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966665"
    }
  ]
}